Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index.
| Autor: | Alanazi J; Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia. khushiazeez@yahoo.co.in., Unnisa A, Ahmad S, Itumalla R, Alanazi M, Alharby TN, Anwar S, Younes KM, Hussain T, Hussain A, Elamine BA, Mohamed OA |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2022 Nov; Vol. 26 (22), pp. 8326-8332. |
| DOI: | 10.26355/eurrev_202211_30365 |
| Abstrakt: | Objective: The current study intends to find out the efficacy of Orlistat in the management of hyperlipidemia, Systolic Blood Pressure (SBP) and Body Mass Index (BMI). Materials and Methods: This retrospective study has evaluated the lipid profiles of the patients, who have been using metformin therapy for Type 2 diabetes. The study has obtained data regarding the parameters like triglyceride, Total cholesterol (TC), LDL cholesterol, HDL cholesterol and LDL/HDL ratio, systolic blood pressure and Body Mass Index (BMI). Random distribution of patients was done into placebo and Orlistat groups. The placebo group received only metformin, and patients in the Orlistat group received Orlistat along with metformin. After 24 weeks, the follow-up study was done, and statistical analysis was conducted. Results: The study found that the Orlistat group has significant improvement (p<0.05) more improvement in LDL cholesterol, HDL cholesterol, Total cholesterol, LDL/HDL Ratio and Triglycerides, while BMI and systolic blood pressure did not show a significant difference between placebo and Orlistat group. Conclusions: This study has concluded that Orlistat can be used for significant improvement in lipid profile. The study also found that Orlistat may not have a significant effect on reducing BMI and blood pressure without adequate lifestyle modification. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|